

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | MNK1 ↓ ↑ | MNK2 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGP 57380 |
++
MNK1, IC50: 2.2 μM |
99%+ | |||||||||||||||||
| Tomivosertib |
+++
MNK1, IC50: 2.4 nM |
++++
MNK2, IC50: 1 nM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | MNK1 is important for its regulation of phosphorylation of eIF4E mediated via the activation of MAP kinase pathways. CGP57380 is a MNK1 inhibitor with IC50 values of 2.2μM and 3μM for inhibition of MNK1 kinase activity in vitro and phosphorylation of eIF4E in cellular assays, respectively. Pretreatment with CGP57380 at concentration of 10μM for 60min could block phosphorylation of eIF4E induced by TNF-α, arsenite, anisomycin, PMA or FCS in 293 cells. Meanwhile, inhibition of MNK1 by CGP-57380 resulted in a dose-dependent increase in the activity of cap-dependent translation in a reporter gene assay with reduced eIF4E phosphorylation in 293 cells. CGP57380 at concentration ranging in 1-10μM resulted in dose-dependent decreases in Ang II–stimulated phosphorylation of eIF4E, protein synthesis, and VSMC hypertrophy of VSMCs. CGP-57380 prevented eIF4E phosphorylation, β-catenin activation, and BC LSC function in vitro at concentration of 10μM and in vivo at dose of 40mg/kg, intraperitoneally, daily, for 3 weeks. |
| Concentration | Treated Time | Description | References | |
| NP69 | 273.44 µM | 72 h | Low toxicity to normal cells | Theranostics. 2017 May 30;7(7):2134-2149. |
| HNE1 | 103.278 µM | 72 h | Inhibition of cell proliferation and colony formation ability | Theranostics. 2017 May 30;7(7):2134-2149. |
| CNE1 | 38.261 µM | 72 h | Inhibition of cell proliferation and colony formation ability | Theranostics. 2017 May 30;7(7):2134-2149. |
| U87MG-luc cells | 10 μM | 3 days | MTT assay showed that combined treatment with CGP57380 and RAD001 significantly inhibited cell proliferation. | J Clin Invest. 2014 Feb;124(2):742-54. |
| LN229 cells | 10 μM | 20 h | Western blot analysis showed that CGP57380 or MNK1 siRNA combined with RAD001 significantly inhibited 4EBP1 phosphorylation at Ser65. | J Clin Invest. 2014 Feb;124(2):742-54. |
| U373 cells | 10 μM | 20 h | Analyzed how MNK1 and mTORC1 signaling pathways regulate the assembly of translation initiation complexes, found that CGP57380 or MNK1 knockdown combined with RAD001 increased 4EBP1 binding to eIF4E. | J Clin Invest. 2014 Feb;124(2):742-54. |
| CEM cells | 4-16 μM | 24 h | CGP57380 dose-dependently suppressed the expression of both phosphor-MNK1 and phosphor-eIF4E, thereby inhibiting downstream targets such as c-Myc and survivin. | Acta Pharmacol Sin. 2018 Dec;39(12):1894-1901. |
| Jurkat cells | 4-16 μM | 24 h | CGP57380 dose-dependently suppressed the expression of both phosphor-MNK1 and phosphor-eIF4E, thereby inhibiting downstream targets such as c-Myc and survivin. | Acta Pharmacol Sin. 2018 Dec;39(12):1894-1901. |
| A549 cells | 20 μM | CGP57380 substantially reduced eIF4G in the eIF4F complex while drastically inhibiting eIF4E phosphorylation | Neoplasia. 2010 Oct;12(10):848-55. | |
| H157 cells | 10-40 μM | 30 min pretreatment followed by 4 h co-treatment | CGP57380 reduced basal p-eIF4E levels and almost completely blocked OA-induced increase in eIF4E phosphorylation | Neoplasia. 2010 Oct;12(10):848-55. |
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice | Orthotopic GBM mouse model | I.p. injection | 25 mg/kg | 4 injections between days 8 and 15 after implantation | Evaluated the effects of CGP57380 alone or in combination with RAD001 in vivo, found that combined treatment significantly inhibited tumor growth. | J Clin Invest. 2014 Feb;124(2):742-54. |
| BALB/c nude mice | Subcutaneous tumor model | Intraperitoneal injection | 25 mg/kg | Three times per week for 3 weeks | Inhibition of tumor growth and metastasis | Theranostics. 2017 May 30;7(7):2134-2149. |
| C57BL/6 mice | LPS-induced acute lung injury model | Intraperitoneal injection | 30 mg/kg | Single dose, pretreated for 30 min before LPS challenge | To evaluate the protective effect of CGP57380 on LPS-induced acute lung injury. Results showed that CGP57380 pretreatment significantly attenuated LPS-induced lung wetry ratio, protein content, total cells and neutrophils in BALF, and decreased the production of pro-inflammatory mediators such as IL-6, TNF-α, and KC. | Biochem Pharmacol. 2021 Apr;186:114499 |
| Sprague-Dawley rats | Experimental model of brain stem death | Bilateral microinjection into RVLM | 5 pmol | Single administration, observed for 180 minutes | To evaluate the effect of CGP57380 on cardiovascular regulation in the brain stem death model. Results showed that CGP57380 pretreatment exacerbated hypotension and blunted the life signal, shortening the pro-life phase. | J Biomed Sci. 2010 Mar 15;17(1):17 |
| Dose | Mice: 20 mg/kg, 50 mg/kg[3] (i.p.) |
| Administration | i.p. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.09mL 0.82mL 0.41mL |
20.47mL 4.09mL 2.05mL |
40.95mL 8.19mL 4.09mL |
|
| CAS号 | 522629-08-9 |
| 分子式 | C11H9FN6 |
| 分子量 | 244.23 |
| SMILES Code | NC1=C2C(NN=C2NC3=CC=C(F)C=C3)=NC=N1 |
| MDL No. | MFCD03861062 |
| 别名 | MNK1 Inhibitor |
| 运输 | 蓝冰 |
| InChI Key | UQPMANVRZYYQMD-UHFFFAOYSA-N |
| Pubchem ID | 11644425 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 5 mg/mL(20.47 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1